JPWO2021212084A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021212084A5 JPWO2021212084A5 JP2022562646A JP2022562646A JPWO2021212084A5 JP WO2021212084 A5 JPWO2021212084 A5 JP WO2021212084A5 JP 2022562646 A JP2022562646 A JP 2022562646A JP 2022562646 A JP2022562646 A JP 2022562646A JP WO2021212084 A5 JPWO2021212084 A5 JP WO2021212084A5
- Authority
- JP
- Japan
- Prior art keywords
- igg
- modified
- constant domain
- feline
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000282324 Felis Species 0.000 claims 17
- 238000006467 substitution reaction Methods 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 241000282326 Felis catus Species 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063011491P | 2020-04-17 | 2020-04-17 | |
| US63/011,491 | 2020-04-17 | ||
| PCT/US2021/027839 WO2021212084A1 (en) | 2020-04-17 | 2021-04-16 | Feline antibody variants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023522030A JP2023522030A (ja) | 2023-05-26 |
| JPWO2021212084A5 true JPWO2021212084A5 (es) | 2024-04-22 |
Family
ID=75870744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562646A Pending JP2023522030A (ja) | 2020-04-17 | 2021-04-16 | ネコ科動物抗体バリアント |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240067730A1 (es) |
| EP (1) | EP4136109A1 (es) |
| JP (1) | JP2023522030A (es) |
| KR (1) | KR20230005158A (es) |
| CN (1) | CN115667300A (es) |
| AU (1) | AU2021257355A1 (es) |
| BR (1) | BR112022020631A2 (es) |
| CA (1) | CA3176434A1 (es) |
| CL (2) | CL2022002856A1 (es) |
| CO (1) | CO2022014684A2 (es) |
| EC (1) | ECSP22080858A (es) |
| IL (1) | IL297290A (es) |
| MX (1) | MX2022012793A (es) |
| PE (1) | PE20230348A1 (es) |
| TW (1) | TW202204404A (es) |
| WO (1) | WO2021212084A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202106478UA (en) | 2019-01-03 | 2021-07-29 | Invetx Inc | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| EP4149969A1 (en) | 2020-05-11 | 2023-03-22 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| JP2023534636A (ja) | 2020-07-10 | 2023-08-10 | インベテックス インコーポレイテッド | 治療薬のネコにおける半減期を増加させるための組成物及びその使用方法 |
| PE20240110A1 (es) * | 2020-09-29 | 2024-01-22 | Zoetis Services Llc | Variantes de anticuerpos felinos |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US5698762A (en) | 1994-12-09 | 1997-12-16 | Dauerman; Leonard | Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons |
| US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
| BRPI0515230A (pt) | 2004-08-19 | 2008-07-15 | Genentech Inc | polipeptìdeos, anticorpos e ácidos nucléicos isolados, composições, vetor de expressão, células hospedeiras isoladas, método para a produção de um anticorpo, artigos manufaturados, métodos de tratamento e para o alìvio de disfunções, métodos de produção e de seleção de um polipeptìdeo, anticorpo de ligação cd20 humanizado, anticorpo anti-her2 isolado e usos de um anticorpo |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP2845865A1 (en) | 2004-11-12 | 2015-03-11 | Xencor Inc. | Fc variants with altered binding to FcRn |
| ES2910305T3 (es) | 2010-08-19 | 2022-05-12 | Zoetis Belgium S A | Anticuerpos anti-NGF y su uso |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| EP2859018B1 (en) | 2012-06-06 | 2021-09-22 | Zoetis Services LLC | Caninized anti-ngf antibodies and methods thereof |
-
2021
- 2021-04-16 WO PCT/US2021/027839 patent/WO2021212084A1/en unknown
- 2021-04-16 JP JP2022562646A patent/JP2023522030A/ja active Pending
- 2021-04-16 US US17/918,860 patent/US20240067730A1/en active Pending
- 2021-04-16 MX MX2022012793A patent/MX2022012793A/es unknown
- 2021-04-16 KR KR1020227035858A patent/KR20230005158A/ko active Search and Examination
- 2021-04-16 IL IL297290A patent/IL297290A/en unknown
- 2021-04-16 BR BR112022020631A patent/BR112022020631A2/pt unknown
- 2021-04-16 PE PE2022002416A patent/PE20230348A1/es unknown
- 2021-04-16 AU AU2021257355A patent/AU2021257355A1/en active Pending
- 2021-04-16 EP EP21724443.3A patent/EP4136109A1/en active Pending
- 2021-04-16 CN CN202180028968.3A patent/CN115667300A/zh active Pending
- 2021-04-16 CA CA3176434A patent/CA3176434A1/en active Pending
- 2021-04-19 TW TW110113948A patent/TW202204404A/zh unknown
-
2022
- 2022-10-17 CL CL2022002856A patent/CL2022002856A1/es unknown
- 2022-10-17 EC ECSENADI202280858A patent/ECSP22080858A/es unknown
- 2022-10-18 CO CONC2022/0014684A patent/CO2022014684A2/es unknown
-
2023
- 2023-11-13 CL CL2023003376A patent/CL2023003376A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7181612B2 (ja) | アルカリ安定性免疫グロブリン結合タンパク質 | |
| US20210162319A1 (en) | Mutated Immunoglobulin-Binding Polypeptides | |
| JP6839101B2 (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| CN110382529B (zh) | 工程化的异源二聚体蛋白质 | |
| JP2021097695A5 (es) | ||
| JP5974342B2 (ja) | アフィニティークロマトグラフィーマトリックス | |
| JP5728392B2 (ja) | 免疫グロブリンの精製 | |
| JP5974343B2 (ja) | アフィニティークロマトグラフィーマトリックス | |
| Sachs et al. | Antibodies to a distinct antigenic determinant of staphylococcal nuclease | |
| JP2020506898A5 (es) | ||
| JPH03139293A (ja) | ヒトインタ―ロイキン―６レセプターに対する抗体 | |
| CN114787193B (zh) | 抗聚合酶的单克隆抗体及其应用 | |
| WO1989007142A1 (en) | Domain-modified constant region antibodies | |
| JP2007252368A (ja) | イムノグロブリン親和性リガンド | |
| CA2645675C (en) | Adsorbents for protein purification | |
| WO2015050153A1 (ja) | 免疫グロブリンＧ（ＩｇＧ）のＦｃ部分を有するタンパク質に対するアフィニティを有する複数のドメイン間をリンカーで結合させて成るタンパク質 | |
| CN111491951A (zh) | 通过疏水相互作用色谱法耗尽轻链错配的抗体变体 | |
| JPWO2021212084A5 (es) | ||
| JPWO2021212081A5 (es) | ||
| JP2015019615A (ja) | プロテインｇの細胞膜外ドメイン変異体の新規な改変型タンパク質 | |
| JP4471721B2 (ja) | 抗インターロイキン２１受容体（ｉｌ−２１ｒ）抗体および本抗体を産生するハイブリドーマ | |
| JP2019172702A (ja) | 目的とする含量で不純物を含むＴＮＦＲ−Ｆｃ融合タンパク質の製造方法 | |
| JP2015003872A (ja) | マウスＩｇＧの精製方法 | |
| WO2024055988A1 (zh) | 免疫球蛋白结合蛋白及其应用 | |
| Better et al. | Production of antibody domains in prokaryotes |